Merck outlines 2026 revenue of $66.8B-$67.3B and EPS of $2.77-$2.82 while investing ahead of Keytruda LOE

Summary

Merck outlined its 2026 guidance, projecting revenue of $66.8 billion to $67.3 billion and earnings per share of $2.77 to $2.82, while investing ahead of the loss of exclusivity for Keytruda. This summary is based only on the headline of the Seeking Alpha report, as no article body was available.

Timeline

1. Seeking Alpha

   29 Oct 2026, 18:10 UTCSource ↗

   Seeking Alpha reports that Merck outlined 2026 revenue of $66.8 billion to $67.3 billion and EPS of $2.77 to $2.82 while investing ahead of the Keytruda loss of exclusivity.